Sunday, November 1, 2026

Moderna Stock Bullish Momentum With A 3.56% Rise Today

ViaNews Editorial Team

December 23, 2020

Moderna Stock Bullish Momentum With A 3.56% Rise Today

The Nasdaq Stock Market ended the session with Moderna rising 3.56% to $130.36 on Wednesday while the Nasdaq Stock Market rose 0.05% to $12,813.90.

Moderna today's close was $130.36, 36.93% under its 52-week high of $178.50.

News about Moderna today

Health Canada authorizes Moderna Covid-19 vaccine. According to today's article on Business Insider, "Health Canada received Moderna's submission on October 12, 2020, and after a thorough, independent review of the evidence, it has determined that the Moderna vaccine meets the Department's stringent safety, efficacy and quality requirements.", "The terms and conditions of the Moderna vaccine authorization require the manufacturer to continue providing information to Health Canada on the safety, efficacy and quality of the vaccine to ensure the benefits of the vaccine continue to be demonstrated through market use."

Moderna shot gets approval in Canada’s expanding vaccine effort. According to today's article on Bloomberg Quint, "Canada's public health authorities approved Moderna Inc.'s coronavirus vaccine, the second shot to be licensed in a country that's secured more doses per person than any other around the world.", ""The different storage and handling requirements of the Moderna Covid-19 vaccine mean that it can be distributed to isolated and remote communities, including the territories.""

Canada authorizes Moderna vaccine. According to today's article on MarketWatch, "Shares of Moderna Inc. were down 0.1% in trading on Wednesday after it said Canada authorized its COVID-19 vaccine for adults. "

Moderna's Sales

Moderna's sales growth is 1841.7% for the ongoing quarter and 19117.5% for the next. The company's growth estimates for the ongoing quarter is a negative 2.7% and positive 660% for the next.

Moderna's Revenue

Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.

Moderna's Stock Yearly Top and Bottom Value

Moderna's stock is valued at $130.36 at 16:12 EST, way below its 52-week high of $178.50 and way above its 52-week low of $17.68.

Moderna's Moving Average

Moderna's worth is way higher than its 50-day moving average of $118.15 and way higher than its 200-day moving average of $81.36.

Previous days news about Moderna

Philippines to start vaccine talks with Moderna by year-end: CNN. According to Bloomberg Quint on Mon Dec 21, "The Philippines will start talks with Moderna Inc. on or before Dec. 30 to secure supply of the company's coronavirus vaccine, Foreign Affairs Secretary Teodoro Locsin said Monday.", ""Moderna is interested in giving an allocation," he said in a live-streamed interview with CNN Philippines, citing Philippine ambassador to the U.S. Jose Manuel Romualdez."

Moderna, biontech post worst day for vaccine stocks in a month. According to Bloomberg Quint on Tue Dec 22, "Tuesday's slide puts a small dent in a rally that has pushed Moderna's shares to jump more than sixfold so far this year while BioNTech has nearly tripled in value.", "Moderna, BioNTech and Pfizer have each traded off their highs since their vaccines received regulatory clearance."

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic AI Goes Operational: Platform Governance, Local Silicon, and the Physical-AI Data Race
In mid-to-late October 2026, enterprise vendors (Cisco, Fortinet, ServiceNow, Intuit, Salesforce/Braze, Adobe) shipped agent governance, AI security and AI-driven customer engagement products, while a parallel hardware wave (NVIDIA RTX Spark laptops, ASUS, Apple's iPad mini, Microsoft's hybrid local/cloud Windows) pushed AI onto local devices. A third strand, physical AI (Encord, Harvest Praxis, Hesai), argues that real-world sensor data and cheaper edge chips are the next bottleneck. The common thread is the shift from AI experimentation to governed, scaled deployment, with Salesforce's Braze acquisition showing consolidation and fintech players like Intuit tying AI to trusted financial data. The facts support a broad industry theme but contain little direct finance or regulatory evidence, so the AI-finance angle is thin.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,532 source documents archived
Query this data → isubstrate.com